Guwahati Mail

Huntingtons Disease Pipeline Landscape Analysis, Clinical Trials: 50+ Companies and 50+ Pipeline Drugs

 Breaking News
  • No posts were found

Huntingtons Disease Pipeline Landscape Analysis, Clinical Trials: 50+ Companies and 50+ Pipeline Drugs

November 15
21:26 2022
Huntingtons Disease Pipeline Landscape Analysis, Clinical Trials: 50+ Companies and 50+ Pipeline Drugs

DelveInsight’s, “Huntington’s Disease Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Huntington’s Disease Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Huntington’s Disease Pipeline Report

  • DelveInsight’s Huntington’s Disease Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
  • The leading Huntington’s Disease Companies are working such as Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others
  • Promising Huntington’s Disease Pipeline therapies such as Pridopidine, Tominersen, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Huntington’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Huntington’s Disease.

 

Recent Developmental Activities in the Huntington’s Disease Pipeline Report

  • In August 2018, European Medicines Agency (EMA) granted PRIME (PRIority MEdicines) designation for the tominersen for the treatment of Huntington’s disease (HD). Ionis Pharmaceuticals entered into a collaboration with Roche to develop and commercialize antisense medicines to treat HD in April 2013.
  • The US FDA granted orphan drug designation to Ionis Pharmaceuticals, for tominersen for the treatment of Huntington’s disease in January 2016.
  • Pridopidine is a highly selective, first in class small molecule which is sigma-1 receptor (S1R) agonist. Pridopidine is currently in late-stage clinical development for Huntington’s disease. Prilenia has an orphan drug designation for pridopidine for the treatment of Huntington’s disease in both the US and Europe.

 

Request a sample and discover the recent advances in Huntington’s Disease Medication @ Huntington’s Disease Clinical Trials

 

Huntington’s Disease Overview

Huntington’s disease is a rare, inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain. It is an autosomal dominant disorder caused by a single defective gene on chromosome 4. The symptoms of Huntington’s Disease include involuntary jerking or writhing movements (chorea), muscle problems, such as rigidity or muscle contracture (dystonia), slow or abnormal eye movements, impaired balance, difficulty with speech or swallowing, difficulty organizing, prioritizing or focusing on tasks, and/or fatigue and loss of energy. A diagnosis of Huntington’s disease is based upon a general physical examination, medical history, and thorough neurological and psychiatric examinations. Treatment for Huntington’s disease is focus on managing the symptoms of the disease, includes medications and psychotherapy. Tetrabenazine (Xenazine) and deutetrabenazine (Austedo), which have been specifically approved by the FDA to suppress the involuntary jerking and writhing movements (chorea) associated with Huntington’s disease.

 

Huntington’s Disease Emerging Drugs

  • Pridopidine: Prilenia Therapeutics
  • Tominersen: Ionis Pharmaceuticals

 

Huntington’s Disease Pipeline Therapeutic Assessment

There are approx. 50+ key companies which are developing the therapies for Huntington’s Disease. The companies which have their Huntington’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.

 

Learn more about the emerging Huntington’s Disease pipeline therapies @ Huntington’s Disease Pipeline Outlook

 

Scope of the Huntington’s Disease Pipeline Report

  • Coverage- Global
  • Huntington’s Disease Therapeutics Assessment by Product Type
  • Huntington’s Disease Therapeutics Assessment by Stage and Product Type
  • Huntington’s Disease Therapeutics Assessment by Route of Administration
  • Huntington’s Disease Therapeutics Assessment by Stage and Route of Administration
  • Huntington’s Disease Therapeutics Assessment by Molecule Type
  • Huntington’s Disease Therapeutics Assessment by Stage and Molecule Type
  • Huntington’s Disease Pipeline Companies- Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others
  • Huntington’s Disease Pipeline therapies- Pridopidine, Tominersen, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Huntington’s Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Huntington’s Disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pridopidine: Prilenia Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug Name: Company Name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical/Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Huntington’s Disease Key Companies
  21. Huntington’s Disease Key Products
  22. Huntington’s Disease- Unmet Needs
  23. Huntington’s Disease- Market Drivers and Barriers
  24. Huntington’s Disease- Future Perspectives and Conclusion
  25. Huntington’s Disease Analyst Views
  26. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Huntington’s Disease drugs?
  • How many Huntington’s Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Huntington’s Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Huntington’s Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Huntington’s Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Got Queries? Get in touch with our Business Development Executive @ Huntington’s Disease Treatment Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories